Notice: Undefined variable: etsa in /www/URVweb-data/vs/wwwa.iispv.cat/donacions/en_estudi_colovoc.html on line 132
Home > Donations > Estudi COLOVOC
COLOVOC study - Early diagnosis of colon and rectal cancer
COLOVOC study - Early diagnosis of colon and rectal cancer
Principal Investigator:
Raquel Cumeras / Jesús Brezmes
Scheme of the project
Research group:
Metabolomics Interdisciplinary Laboratory (MiL@b)
Descripció i característiques
The project called COLOVOC (Reliable and specific urinary biomarkers for colorectal cancer) aims to find biomarkers for the diagnosis of colon and rectal cancer at an early stage. To this end, it is anticipated that a consistent diagnosis, with high sensitivity and selectivity through metabolomics science, can be achieved with a urine collection.
In colon and rectal cancer, age is a risk factor, as is food
Currently, the protocol established by the Spanish health system for the early detection of colon and rectal cancer is based on a request by letter to the population of more than 50 years, a sample of feces, and if there is any indication, is programmed a colonoscopy. Although the early detection program has been shown to reduce the mortality of patients with colon and rectal cancer, the inconvenience of collecting stool samples causes that only 40% of the population at the age of screening does it, although it is for your health.
The study proposes an easy collection of samples through a urine sample early in the morning, anticipating that with the change of sample types to be analyzed (urine instead of stool), there is a considerable increase in participation of the population subject to screening.
Search for biomarkers for the effectiveness in the diagnosis of colon and rectal cancer
Researchers believe that through biofluids such as urine and blood (both plasma and serum), metabolites that are related to the presence of tumors of cancer origin of different diseases can be detected, such as example can be cancer of colon and rectum, pancreas, bladder, and breast. Diagnostic biomarkers are sought that are not influenced by any external factor, such as eating habits, cultural, environmental, sedentary life, etc.
It is contemplated to do the study with different cohorts and laboratories to verify the repeatability and scientific validity of the conclusions that are obtained, to cross-validate the samples.
Participants include: The University Hospital San Joan de Reus, the American University of Yale and the University of California, Davis, as well as the start-up based in Tarragona, specialized in diagnostic tests in metabolomics, Biosfer Teslab, S.L.
